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commonly used patient-reported outcome measures (PROMs)—the SF-36 Physical Component Scale (SF-36 PCS), 
WOMAC, IKDC, and Lysholm. Each PROM was completed pre- and 6 and 12 months post-surgery. At 6 and 12 months, 
an additional ‘‘then’’ version of each form was also completed. The ‘‘then’’ version was identical to the original except that 
patients were instructed to assess how they were prior to ACI. Traditional change, response shift adjusted change, and 
response shift magnitude were calculated at 6 and 12 months. T tests (p \ 0.05) were used to compare traditional change to 
response-shift-adjusted change, and response shift magnitude values to previously established minimal detectable change.
There were no differences between traditional change and response-shift-adjusted change for any of the PROMs. The mean 
response shift magnitude value of the WOMAC at 6 months (15 ± 14, p = 0.047) was greater than the previously established 
minimal detectable change (10.9). The mean response shift magnitude value for the SF-36 PCS at 12 months (9.4 ± 6.8, p = 
0.017) also exceeded the previously established minimal detectable change (6.6). There was no evidence of a group-level 
effect for response shift. These results support the validity of pre-test/post-test research designs in evaluating treat- ment 
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Abstract
Purpose Response shift is the phenomenon by which an
individual’s standards for evaluation change over time. The
purpose of this study was to determine whether patients
undergoing autologous chondrocyte implantation (ACI)
experience response shift.
Methods Forty-eight patients undergoing ACI partici-
pated. The ‘‘then-test’’ method was used to evaluate
response shift in commonly used patient-reported outcome
measures (PROMs)—the SF-36 Physical Component Scale
(SF-36 PCS), WOMAC, IKDC, and Lysholm. Each PROM
was completed pre- and 6 and 12 months post-surgery. At
6 and 12 months, an additional ‘‘then’’ version of each
form was also completed. The ‘‘then’’ version was identical
to the original except that patients were instructed to assess
how they were prior to ACI. Traditional change, response
shift adjusted change, and response shift magnitude were
calculated at 6 and 12 months. T tests (p \ 0.05) were used
to compare traditional change to response-shift-adjusted
change, and response shift magnitude values to previously
established minimal detectable change.
Results There were no differences between traditional
change and response-shift-adjusted change for any of the
PROMs. The mean response shift magnitude value of the
WOMAC at 6 months (15 ± 14, p = 0.047) was greater
than the previously established minimal detectable change
(10.9). The mean response shift magnitude value for the
SF-36 PCS at 12 months (9.4 ± 6.8, p = 0.017) also
exceeded the previously established minimal detectable
change (6.6).
Conclusions There was no evidence of a group-level
effect for response shift. These results support the validity
of pre-test/post-test research designs in evaluating treat-
ment effects. However, there is evidence that response
shifts may occur on a patient-by-patient basis, and scores
on the WOMAC and SF-36 in particular may be influenced
by response shift.
Level of evidence II.
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Introduction
To assess function or health-related quality of life (HRQL),
patients are often asked to evaluate their well-being using a
self-report instrument to document patient-reported out-
come measures (PROMs). However, PROMs may be
influenced by response shift [44]. Response shift is the
phenomenon by which an individual’s self-evaluation of a
construct changes due to a change in internal standards of
measurement (recalibration), a change in values or priori-
ties (reprioritization), or a personal redefinition of the tar-
get construct (reconceptualization) [48]. Response shift
may interfere with the ability to accurately detect changes
in patient’s health. Response shift has been observed
among terminal illness and chronic disease patients where
physical health deteriorates, yet their self-reported HRQL
remains stable [16, 34, 45, 47, 50, 53, 55]. It has been
hypothesized that these changes may be a result of
changing values, standards, and priorities [44]. Addition-
ally, response shift has been previously observed among
knee arthroplasty and microfracture patients [1, 37, 38, 57].
While early results for autologous chondrocyte
implantation (ACI) [5] outcomes are promising, the exist-
ing literature primarily reports outcomes using PROMs [4,
6–9, 11–14, 17, 23–25, 27, 31–33, 36, 41, 52, 56].
Although PROMs are used frequently in the orthopaedic
literature, the traditional pre–post-test research designs
used may be influenced by response shift phenomenon. In
particular, the extended preparation and rehabilitation
required for ACI, combined with the inherent expectations
associated with surgery, may make patients prone to
response shift [39]. If the PROMs frequently used to
evaluate ACI outcomes are subject to a response shift, then
reported outcomes may under- or over-estimate the effec-
tiveness of existing articular cartilage treatments, calling
into question the validity of much of the existing ACI
outcomes literature.
The purpose of this study was to determine whether
patients undergoing ACI experience response shift. The
International Knee Documentation Committee (IKDC)
Subjective Knee Evaluation Form, the Western Ontario and
McMaster Osteoarthritis Index (WOMAC), and the medi-
cal outcomes study 36-item short-form health survey
Physical Component Scale (SF-36 PCS) rely heavily on
subjective evaluations of function and pain levels, which
may be influenced by response shift. Therefore, it was
hypothesized that these common ACI outcome instruments
would demonstrate the evidence of a response shift. In
contrast, the Lysholm Knee Scale (Lysholm) focuses on the
capacity to perform specific tasks rather than the ease or
pain associated with task performance; therefore, it was
hypothesized that Lysholm scores would not be influenced
by response shift.
Materials and methods
Patients were prospectively recruited from an active car-
tilage centre within a public university affiliated sports
medicine clinic. Inclusion criteria were the following:
planned ACI surgery to the knee, willingness to participate,
and no uncorrectable contraindications to ACI such as
extensive degenerative joint disease, insufficient meniscus,
or unstable knee. There were no exclusions based on the
limb malalignment if the malalignment was corrected prior
to or at the time of surgery via high tibial osteotomy or
tibial tubercle transfer. Patients undergoing concomitant
meniscal transplant were excluded. A total of 56 consec-
utive patients who met eligibility requirements were
approached to participate in this study (Fig. 1). The final
participating enrolment for this study was 48 patients (29
males, 19 females, 35.1 ± 8.0 yrs, 180.7 ± 31.7 cm,
92.4 ± 20.3 kg). Among these patients, 24 underwent ACI
to the patellofemoral joint with a tibial tubercle transfer, 2
underwent ACI to the lateral femoral condyle, and the
remaining 22 underwent ACI to the femoral condyle, of
which 4 also had a concomitant high tibial osteotomy. The
mean number of defects treated per patient was 1.5 ± 0.6
with an average treatment area of 8.7 ± 6.9 cm2 (range
1.9–39.0 cm2) as measured intraoperatively. All partici-
pants signed a university-approved institutional review
board consent form.
Surgical procedures and rehabilitation
All patients underwent a two-step ACI procedure per-
formed by the same surgeon (XX). During the first pro-
cedure, a limited chondroplasty was performed and the
lesion was evaluated arthroscopically. At this time, a
biopsy was obtained from the intercondylar notch
(100–200 mg cartilage). This sample was sent to a com-
mercial laboratory where it was cultured and expanded
(Carticel, Genzyme Corp., Cambridge, MA). In a second
surgical procedure, chondrocyte implantation was per-
formed using a formal arthrotomy. First, the defect or
defects were prepared using a curette to debride down to
the subchondral plate with stable edges. A type I/III col-
lagen membrane (Geistlich Bio-Gide(R), Geistlich Pharma
North America Inc., Princeton, New Jersey) was shaped to
match the defect. Sutures and fibrin glue (Tisseel, Baxter
Healthcare Corp., Deerfield, IL) were used to adhere the
membrane over the defect to form a water-tight seal. The
chondrocytes in suspension were then injected beneath the
membrane into the defect through a small portal remaining
at the edge of the collagen membrane. The portal was then
closed and sealed with sutures and additional fibrin glue.
All patients followed standardized rehabilitation proto-
cols following surgery [26]. All patients were braced in full
extension and were non-weight bearing for 2 weeks post-
operatively. Toe-touch weight bearing was permitted from
2 to 4 weeks with partial weight bearing from 4 to 6 weeks
and progression to full weight bearing between weeks 6
and 12. Continuous passive motion was prescribed for all
patients for 6–8 h per day for 6 weeks. For defects in the
tibiofemoral joint, knee braces were gradually unlocked
between 2 and 4 weeks as quadriceps control was gained.
For defects to the patellofemoral joint, knees were braced
in full extension for weight bearing through 4 weeks
postoperative and then were gradually unlocked as quad-
riceps control was gained between weeks 4 and 6. Once
good quadriceps control was gained, all patients were
transitioned to a hinged knee sleeve. All patients were
recommended to abstain from high-intensity cutting or
pivoting activity until at least 12 months post-ACI.
Outcome measures
Patient-reported outcomes
The PROMs used in this study were the SF-36 PCS [29, 30,
54], the WOMAC [3], the IKDC [21], and the Lysholm
[49]. Reliability among cartilage patients has been previ-
ously evaluated for each of these instruments [3, 21, 22, 28,
29, 40]. A researcher independent of the treating physician
reviewed each instrument with the patients and was
available to answer any questions they may have had. All
PROMs were completed prior to implantation and at 6 and
12 months post-surgery.
Assessment of response shift
One of the most common statistical approaches for mea-
suring response shift is the then-test method (Fig. 2) [18,
19]. This approach is identical to a traditional pre-test/post-
test method with the exception that subjects complete an
additional ‘‘then-test’’ assessment at the same session as
their post-test assessment. For the then-test, subjects are
instructed to assess how they were at the time of the pre-
test, prior to the intervention. The rationale for this design
is that by completing the then-test and the post-test at the
same time, subjects will provide responses utilizing the
same frame of reference and calibration standards for both.
In a pre-/post-design, traditional change (TC) is the dif-
ference between post-test and pre-test scores and is the
only variable of interest. With the then-test method,
response shift is calculated as the difference between the
then-test and the pre-test and the response-shift-adjusted
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Fig. 2 Then-test method for assessing response shift. For the then-
test method, patients are requested to complete an outcome instru-
ment three times. First pre-treatment (pre-test), again at a specified
post-treatment time point (post-test), and at that same post-treatment
time point, they also complete a then-test on which they are asked to
retrospectively rate how they were at the pre-treatment time point.
From these three scores, response shift, response shift magnitude,
traditional change, and response-shift-adjusted change can then be
calculated. In the present study, post and then evaluations were
completed at 6 and 12 months postoperatively
change (RSAC) is considered to be the difference between
the post-test and the then-test.
Statistical analysis
Apriori power analysis using previously published
12-month response shift values in orthopaedic knee
patients [37] (with PROM standard deviation values that
were comparable to those previously observed in our own
internal cartilage and ligament patient registry) demon-
strated a need to enrol 35 patients to achieve sufficient
power (0.80) to detect a response shift with a = 0.05.
Main outcome measures
The dependent variables of response shift, response shift
magnitude, TC, and RSAC were calculated for the IKDC,
Lysholm, SF-36 PCS, and WOMAC from pre-operation to
6 and 12 months post-ACI as described in Fig. 2.
Group-level effect
To investigate the occurrence of a group-level response
shift, paired t tests were used to compare then-test with pre-
test scores and to compare TC with RSAC for each PROM.
Significant t test results (p \ 0.05) would support the
occurrence of a group-level effect with a consistent
response shift occurring across patients.
Individual-level effect
To investigate the occurrence of an individual-level
(patient-by-patient) effect for response shift, response shift
magnitude was calculated as the absolute value of the
response shift for each PROM. One-sample t tests were
used to compare the response shift magnitude with previ-
ously established minimal detectable changes (MDCs) for
each PROM instrument (p \ 0.05). The MDC at 6- and
12-month follow-up has been previously established
among patients post-ACI for the IKDC (15.6 points at
6 months; 13.7 points at 12 months), WOMAC (10.9,
15.3), and SF-36 PCS (8.3, 6.6) [15]. For the Lysholm
scale, an MDC of 14 was calculated from previously
published reliability and ICC values among patients
awaiting surgery for chondral defects [2, 22].
Results
Study enrolment and follow-up is presented in Fig. 1. Main
outcome measures are reported in Table 1. No group-level
effect for response shift was observed. There were no
differences between pre-test and then-test scores for any of
the PROMs evaluated. There were also no differences
between RSAC and TC, and none of the mean response
shift values exceeded previously established MDC values.
Individual-level analysis
Response shift magnitude values were used to determine
the number of subjects that experienced a response shift
beyond the MDC at the 6- and 12-month time points for
each PROM instrument. At 6 months, it was observed that
there was a response shift beyond the MDC for 17 patients
assessed via the IKDC, 16 patients for the SF-36 PCS, 15
patients for the Lysholm, and 23 patients for the WOMAC.
At the 12-month time point, 10 patients for the IKDC, 23
patients for the SF-36 PCS, 17 patients for the Lysholm,
and 14 patients for the WOMAC experienced response
shifts that exceeded the MDC. Overall, 13 patients at
6 months and 7 patients at 12 months demonstrated the
evidence of a response shift on at least 3 of the four
instruments utilized. The only PROMs to show a signifi-
cant response shift at an individual level across patients
were the total WOMAC score at 6 months and the SF-36
PCS at 12 months. The mean response shift magnitude
value for the WOMAC at 6 months was 15 ± 14, which
was significantly greater than the MDC over 6 months of
10.9 established by Greco et al. [15] (p = 0.047). The
mean response shift magnitude value for the SF-36 PCS
(9.4 ± 6.8) at 12 months also exceeded the previously
established MDC (6.6) [15] over a 12-month follow-up
(p = 0.017).
Discussion
The key finding of the present study was that traditional
pre–post-test methods for evaluating PROMs appear valid
for assessing group-level treatment effects following ACI.
No group-level effects for response shift were observed.
These results fail to support the hypothesis that response
shift would be evident for the IKDC, SF-36 PCS, and
WOMAC, but the results do support the hypothesis that no
response shift would be observed for the Lysholm.
A significant difference between pre-test and then-test
scores for the WOMAC [37, 38] and the SF-36 PCS [37]
has been previously reported at 6 and 12 months following
knee arthroplasty. Similarly, a response shift was reported
using the Lysholm scale among patients with a median of
34 months following knee microfracture [1]. Upon initial
review, our failure to observe a group-level response shift
is in disagreement with the previous work [1, 37, 38] in
orthopaedic knee patients. However, upon further exami-
nation, the values observed in the present study are very
similar to those reported elsewhere. In the present study,
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mean RS values of -5 ± 19 and -4 ± 18 for the Lysholm
were observed compared to a median RS of -7 by Balain
et al. [1] Similarly, we observed mean RS values of 5 ± 20
and 2 ± 17 for the WOMAC and 1.0 ± 10.4 and
1.4 ± 11.6 for the SF-36 PCS, compared with previously
reported mean WOMAC RS values of 3.8 ± 19.5,
5.5 ± 16.9, and 6.7 ± 15.5 and SF-36 PCS values of
-1.7 ± 8.1 and -3.2 ± 7.9 [37, 38]. In all cases, the mean
or median differences between then-test and pre-test scores
were less than the previously established MDC scores for
each instrument, and standard deviations or reported ranges
were quite high. However, the larger sample sizes in the
previous studies, ranging from 53 [1] to 234 [37], resulted
in statistically significant RS values, leading the authors to
conclude that a response shift had occurred.
By examining actual mean RS values and standard
deviations, it can be concluded that the group effect for
response shift observed in previous studies was no more
clinically meaningful than those observed in the present
study. This conclusion was reiterated by the previous
authors who conceded that although a statistically signifi-
cant response shift had occurred, adjusting for the response
shift did not change clinical conclusions regarding treat-
ment efficacy [1, 37, 38]. Based on the present study and
previous reports, a slight group effect for response shift
may occur among postoperative orthopaedic knee patients;
however, this response shift is not substantial enough on a
group level to invalidate the use of traditional pre–post-
outcomes assessment methods.
In comparing response shift magnitude values with
previously established MDC values for articular cartilage
patients, a statistically significant response shift was
observed on an individual level for the WOMAC at
6 months (p = 0.047) and the SF-36 PCS at 12 months
(p = 0.017). Although the WOMAC and SF-36 PCS scores
did not demonstrate a group-level effect for response shift,
the mean response shift magnitude observed on WOMAC
and SF-36 PCS scores did exceed MDC values—meaning
individual patients did exhibit a response shift. However,
some patients’ then-test scores recalibrated positively
(then-test [ pre-test), while others shifted negatively
(then-test \ pre-test) as a result mean response shift values
were not statistically significant, but WOMAC and SF-36
response shift magnitude values were significant. However,
response shift magnitude values suggest that WOMAC and
SF-36 PCS scores are susceptible to response shift on the
individual patient level. If WOMAC and/or SF-36 PCS
scores are being used to track treatment progress of an
individual patient, response shift should be taken into
consideration.
Additional analyses using MDC values suggested that
some individual patients may experience a clinically rele-
vant response shift across PROM instruments with 13
patients at 6 months and 7 patients at 12 months observed
to have response shift magnitude values exceeding MDC
values on at least 3 out of 4 PROMs. The direction of the
response shift is important on a group level to evaluate the
influence of response shift on interpretation of overall
treatment effects across patients. However, because it is
clear that patients may experience either a positive or
negative response shift, averaging RS values across
patients may obscure the occurrence of a true, albeit non-
uniform, response shift.
Question structure may contribute to the WOMAC and
SF-36 PCS being more influenced by response shift than
the IKDC or Lysholm. The versions of the WOMAC and
the SF-36 included in this study rely heavily on 5- or
6-item Likert-like response choices. For example, WO-
MAC response choices include ‘‘none’’, ‘‘mild’’, ‘‘moder-
ate’’, ‘‘severe’’, or ‘‘extreme’’. This type of scale can be
highly subjective and may be prone to scale recalibration
and situational interpretation [35]. Depending on the
patient’s prior experiences, mild and moderate may have
different meanings over time as the patient has more
information and new experiences for comparison. While
other PROM instruments contain some similarly structured
questions, the WOMAC and SF-36 provide significantly
less context from which the patient is asked to answer the
questions. In contrast, the IKDC and the Lysholm provide
the patient with reference criteria creating meaningful
standards around which one can anchor his or her internal
scale. For example, the IKDC asks ‘‘What is the highest
level of activity you are able to perform without significant
giving way in your knee?’’ and in addition to providing
response choices such as ‘‘very strenuous’’ or ‘‘strenuous’’
examples of each level of activity are provided, such as
‘‘very strenuous activities like jumping or pivoting as in
basketball or soccer’’. By placing the dysfunction of giving
way in the participation context of soccer or basketball, the
instrument is cueing the patient to a specific sample of
relevant experiences or activities from which to evaluate
his or her own function. By providing scale anchors and
directing the patient towards a specific sample of experi-
ences, the IKDC and Lysholm appear to reduce the risk of
significant variation in scale and conceptualization between
and within patients over time.
Personal and environmental factors may explain why
among cartilage patients response shift seems to be an
individual and not a group phenomenon. Unlike a terminal
disease, which will likely impact every aspect of life, the
impact of physical limitations secondary to knee surgery
vary from person to person depending on factors such as
employment status, pre-injury activity level, social support,
and preoperative expectations. These contextual factors
have previously been referred to as ‘‘antecedents’’ in
Spranger and Schwartz’s model of response shift and
HRQL [48]. This model of response shift stresses the
importance of variables such as personality, sociodemo-
graphics, access to care, physical environment, expecta-
tions, and spiritual identity on health outcomes. All of these
factors may vary from person to person, further explaining
the great variability observed and why evidence of a
response shift may exist on an individual level, but not on
the group level. Awareness of this individual response shift
may be highly relevant to clinicians as they try to reconcile
changes in patient-reported health (or lack thereof) with
observations of changes in physical health and perfor-
mance [20]. Clinicians may strongly benefit by having an
awareness of what factors may make an individual prone to
a response shift and how those factors can be utilized to
provide the individual with the highest possible self-per-
ceived HRQL.
By asking patients to recall their level of function
6–12 months prior, the then-test method may be prone to
recall bias [42]. However, the then-test method has been
demonstrated as having convergent validity with more
complicated methods of evaluating response shift including
structural equation modelling and analysis of covariance,
which require much larger samples sizes than were avail-
able in this investigation [42, 51]. Additional research has
demonstrated that recall bias alone was unable to explain
changes in then-test scores observed among multiple
sclerosis patients or human immunodeficiency virus/
acquired immune disease syndrome patients, and at least a
portion of observed changes could be attributed to response
shift [43, 46]. Finally, the use of the then-test method
allowed for direct comparison to previous investigations of
response shift in orthopaedic knee patients.
Additionally, it is cautioned that the conclusions drawn
from this study must be limited to the patient population
and time points investigated. The study population inclu-
ded ACI patients undergoing a variety of concomitant
procedures. While this patient sample may seem hetero-
geneous relative to those reported commonly in the liter-
ature for ACI, we believe including complex patients in our
sample actually increases the generalizability of our find-
ings to true ACI populations treated in clinical practice
[10]. Similarly, we only examined response shift within the
first year following ACI and cannot draw conclusions
concerning the effect of response shift on longer-term
outcomes.
Conclusions
These results support the validity of traditional pre-test/
post-test research designs in evaluating short-term treat-
ment effects following cartilage repair. However, there is
evidence that response shift may occur on an individual
level on a patient-by-patient basis, and short-term scores on
the WOMAC and SF-36 PCS in particular may be influ-
enced by response shift. On a clinical level, recognizing the
occurrence of a response shift may be key in evaluating
short-term treatment progress for individual patients. This
is particularly true for treatments such as ACI where
physicians depend heavily on patient self-report and
appraisal of progress because tools for diagnostic evalua-
tion are limited and not always feasible or cost-effective.
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